Intramuscular Ketamine use as an Antisuicidal drug
Not Applicable
- Conditions
- Health Condition 1: F322- Major depressive disorder, singleepisode, severe without psychotic features
- Registration Number
- CTRI/2022/09/045713
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Having suicidal ideations (MADRS-SI score >3)
2. Who gave consent
Exclusion Criteria
1. Present diagnosis or antecedents of clinically relevant cardiovascular disorders such as stroke, heart attack, etc.
2. Present or past diagnosis of glaucoma, intracranial hypertension.
3. Current diagnosis of schizophrenia as defined in the ICD-11.
4. Patients with any known hypersensitivity to ketamine.
5. patients who are hemodynamically unstable.
6. Delirious patients.
7. Pregnancy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MADRS SI score, vitals, adverse events are to be checked to see effectiveness and safety of intramuscular ketamine (0.5 mg/k)Timepoint: baseline, 2 hours post injection, then on day 1,3,7,14,21,28.(1 month follow up)
- Secondary Outcome Measures
Name Time Method not applicableTimepoint: not applicable